Trials / Unknown
UnknownNCT01363739
Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab
Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 265 (estimated)
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.
Conditions
Timeline
- Start date
- 2009-04-01
- First posted
- 2011-06-02
- Last updated
- 2011-06-02
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01363739. Inclusion in this directory is not an endorsement.